Skip to main content
SpringerLink
Log in

Molecular Genetics of Thyroid Cancer

  • Chapter
  • First Online:
Management of Differentiated Thyroid Cancer

  • 838 Accesses

Abstract

In recent years, knowledge of the genetics of differentiated thyroid carcinomas has been rapidly increasing. Mutations identified in papillary thyroid cancer (PTC) can be subdivided into BRAF- or RAS-like and include BRAF, RET/PTC, RAS, TRK, TERT, and EIF1AX. The leading genetic alterations in follicular thyroid carcinoma (FTC) are RAS, PAX8/PPARG, PTEN, PI3K/AKT pathway, and IDH1. Chapter 2 will provide an overview of common mutations and rearrangements in differentiated thyroid carcinoma in association with their clinical and pathologic characteristics and the current state of the rapidly advancing field.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. DeLellis RA, Lloyd RV, Heitz PU, Eng C. Pathology and genetics of tumours of endocrine organs, World Health Organization Classification of Tumours. Lyon: IARC; 2004.

    Google Scholar 

  2. Atlas TCG. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014;159(3):676–90.

    Article  CAS  Google Scholar 

  3. Giordano TJ. Follicular cell thyroid neoplasia: insights from genomics and The Cancer Genome Atlas research network. Curr Opin Oncol. 2016;28(1):1–4.

    Article  CAS  PubMed  Google Scholar 

  4. Puxeddu E, Moretti S, Elisei R, Romei C, Pascucci R, Martinelli M, et al. BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. J Clin Endocrinol Metab. 2004;89(5):2414–20.

    Article  CAS  PubMed  Google Scholar 

  5. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003;63(7):1454–7.

    CAS  PubMed  Google Scholar 

  6. Soares P, Trovisco V, Rocha AS, Lima J, Castro P, Preto A, et al. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene. 2003;22(29):4578–80.

    Article  CAS  PubMed  Google Scholar 

  7. Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B, et al. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst. 2003;95(8):625–7.

    Article  CAS  PubMed  Google Scholar 

  8. Xu X, Quiros RM, Gattuso P, Ain KB, Prinz RA. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res. 2003;63(15):4561–7.

    CAS  PubMed  Google Scholar 

  9. Nikiforov YE. RET/PTC rearrangement in thyroid tumors. Endocr Pathol. 2002;13(1):3–16.

    Article  CAS  PubMed  Google Scholar 

  10. Tallini G, Asa SL. RET oncogene activation in papillary thyroid carcinoma. Adv Anat Pathol. 2001;8(6):345–54.

    Article  CAS  PubMed  Google Scholar 

  11. Karga H, Lee JK, Vickery Jr AL, Thor A, Gaz RD, Jameson JL. Ras oncogene mutations in benign and malignant thyroid neoplasms. J Clin Endocrinol Metab. 1991;73(4):832–6.

    Article  CAS  PubMed  Google Scholar 

  12. Ezzat S, Zheng L, Kolenda J, Safarian A, Freeman JL, Asa SL. Prevalence of activating ras mutations in morphologically characterized thyroid nodules. Thyroid. 1996;6(5):409–16.

    Article  CAS  PubMed  Google Scholar 

  13. Namba H, Rubin SA, Fagin JA. Point mutations of ras oncogenes are an early event in thyroid tumorigenesis. Mol Endocrinol (Baltimore, MD). 1990;4(10):1474–9.

    Article  CAS  Google Scholar 

  14. Hara H, Fulton N, Yashiro T, Ito K, DeGroot LJ, Kaplan EL. N-ras mutation: an independent prognostic factor for aggressiveness of papillary thyroid carcinoma. Surgery. 1994;116(6):1010–6.

    CAS  PubMed  Google Scholar 

  15. Basolo F, Pisaturo F, Pollina LE, Fontanini G, Elisei R, Molinaro E, et al. N-ras mutation in poorly differentiated thyroid carcinomas: correlation with bone metastases and inverse correlation to thyroglobulin expression. Thyroid. 2000;10(1):19–23.

    Article  CAS  PubMed  Google Scholar 

  16. Rabes HM, Demidchik EP, Sidorow JD, Lengfelder E, Beimfohr C, Hoelzel D, et al. Pattern of radiation-induced RET and NTRK1 rearrangements in 191 post-chernobyl papillary thyroid carcinomas: biological, phenotypic, and clinical implications. Clin Cancer Res. 2000;6(3):1093–103.

    CAS  PubMed  Google Scholar 

  17. Howell GM, Hodak SP, Yip L. RAS mutations in thyroid cancer. Oncologist. 2013;18(8):926–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Vasko V, Ferrand M, Di Cristofaro J, Carayon P, Henry JF, de Micco C. Specific pattern of RAS oncogene mutations in follicular thyroid tumors. J Clin Endocrinol Metab. 2003;88(6):2745–52.

    Article  CAS  PubMed  Google Scholar 

  19. Nikiforova MN, Biddinger PW, Caudill CM, Kroll TG, Nikiforov YE. PAX8-PPARgamma rearrangement in thyroid tumors: RT-PCR and immunohistochemical analyses. Am J Surg Pathol. 2002;26(8):1016–23.

    Article  PubMed  Google Scholar 

  20. Hou P, Liu D, Shan Y, Hu S, Studeman K, Condouris S, et al. Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin Cancer Res. 2007;13(4):1161–70.

    Article  CAS  PubMed  Google Scholar 

  21. Liu Z, Hou P, Ji M, Guan H, Studeman K, Jensen K, et al. Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J Clin Endocrinol Metab. 2008;93(8):3106–16.

    Article  CAS  PubMed  Google Scholar 

  22. Murugan AK, Bojdani E, Xing M. Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer. Biochem Biophys Res Commun. 2010;393(3):555–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Xing M, Liu R, Liu X, Murugan AK, Zhu G, Zeiger MA, et al. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. J Clin Oncol. 2014;32(25):2718–26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Melo M, da Rocha AG, Vinagre J, Batista R, Peixoto J, Tavares C, et al. TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. J Clin Endocrinol Metab. 2014;99(5):E754–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Dhomen N, Marais R. BRAF signaling and targeted therapies in melanoma. Hematol Oncol Clin North Am. 2009;23(3):529–45. ix

    Article  PubMed  Google Scholar 

  26. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949–54.

    Article  CAS  PubMed  Google Scholar 

  27. Gunson TH, Hashim N, Sharpe GR. Generalized lentiginosis, short stature, and multiple cutaneous nodules--quiz case. LEOPARD syndrome (LS) associated with multiple granular cell tumors (GCTs). Arch Dermatol. 2010;146(3):337–42.

    Article  PubMed  Google Scholar 

  28. Cantwell-Dorris ER, O’Leary JJ, Sheils OM. BRAFV600E: implications for carcinogenesis and molecular therapy. Mol Cancer Ther. 2011;10(3):385–94.

    Article  CAS  PubMed  Google Scholar 

  29. Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab. 2003;88(11):5399–404.

    Article  CAS  PubMed  Google Scholar 

  30. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. 2007;1773(8):1263–84.

    Article  CAS  PubMed  Google Scholar 

  31. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, et al. Patterns of somatic mutation in human cancer genomes. Nature. 2007;446(7132):153–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Sithanandam G, Druck T, Cannizzaro LA, Leuzzi G, Huebner K, Rapp UR. B-raf and a B-raf pseudogene are located on 7q in man. Oncogene. 1992;7(4):795–9.

    CAS  PubMed  Google Scholar 

  33. Mercer KE, Pritchard CA. Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta. 2003;1653(1):25–40.

    CAS  PubMed  Google Scholar 

  34. Bamford S, Dawson E, Forbes S, Clements J, Pettett R, Dogan A, et al. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer. 2004;91(2):355–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  35. Yoon S, Seger R. The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors (Chur, Switzerland). 2006;24(1):21–44.

    Article  CAS  Google Scholar 

  36. Vu-Phan D, Koenig RJ. Genetics and epigenetics of sporadic thyroid cancer. Mol Cell Endocrinol. 2014;386(1–2):55–66.

    Article  CAS  PubMed  Google Scholar 

  37. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 2004;116(6):855–67.

    Article  CAS  PubMed  Google Scholar 

  38. Nikiforov YE. Molecular analysis of thyroid tumors. Mod Pathol. 2011;24(Suppl 2):S34–43.

    Article  CAS  PubMed  Google Scholar 

  39. Trovisco V, Soares P, Preto A, de Castro IV, Lima J, Castro P, et al. Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients’ age but not with tumour aggressiveness. Virchows Arch. 2005;446(6):589–95.

    Article  CAS  PubMed  Google Scholar 

  40. Castro P, Rebocho AP, Soares RJ, Magalhaes J, Roque L, Trovisco V, et al. PAX8-PPARgamma rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma. J Clin Endocrinol Metab. 2006;91(1):213–20.

    Article  CAS  PubMed  Google Scholar 

  41. Ciampi R, Knauf JA, Kerler R, Gandhi M, Zhu Z, Nikiforova MN, et al. Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. J Clin Invest. 2005;115(1):94–101.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Adeniran AJ, Zhu Z, Gandhi M, Steward DL, Fidler JP, Giordano TJ, et al. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol. 2006;30(2):216–22.

    Article  PubMed  Google Scholar 

  43. Lin KL, Wang OC, Zhang XH, Dai XX, Hu XQ, Qu JM. The BRAF mutation is predictive of aggressive clinicopathological characteristics in papillary thyroid microcarcinoma. Ann Surg Oncol. 2010;17(12):3294–300.

    Article  PubMed  Google Scholar 

  44. Lee X, Gao M, Ji Y, Yu Y, Feng Y, Li Y, et al. Analysis of differential BRAF(V600E) mutational status in high aggressive papillary thyroid microcarcinoma. Ann Surg Oncol. 2009;16(2):240–5.

    Article  PubMed  Google Scholar 

  45. Flint A, Davenport RD, Lloyd RV. The tall cell variant of papillary carcinoma of the thyroid gland. Comparison with the common form of papillary carcinoma by DNA and morphometric analysis. Arch Pathol Lab Med. 1991;115(2):169–71.

    CAS  PubMed  Google Scholar 

  46. Johnson TL, Lloyd RV, Thompson NW, Beierwaltes WH, Sisson JC. Prognostic implications of the tall cell variant of papillary thyroid carcinoma. Am J Surg Pathol. 1988;12(1):22–7.

    Article  CAS  PubMed  Google Scholar 

  47. Prendiville S, Burman KD, Ringel MD, Shmookler BM, Deeb ZE, Wolfe K, et al. Tall cell variant: an aggressive form of papillary thyroid carcinoma. Otolaryngology. 2000;122(3):352–7.

    CAS  Google Scholar 

  48. Xing M, Clark D, Guan H, Ji M, Dackiw A, Carson KA, et al. BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. J Clin Oncol. 2009;27(18):2977–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Ricarte-Filho JC, Ryder M, Chitale DA, Rivera M, Heguy A, Ladanyi M, et al. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res. 2009;69(11):4885–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Durante C, Puxeddu E, Ferretti E, Morisi R, Moretti S, Bruno R, et al. BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J Clin Endocrinol Metab. 2007;92(7):2840–3.

    Article  CAS  PubMed  Google Scholar 

  51. Chakravarty D, Santos E, Ryder M, Knauf JA, Liao XH, West BL, et al. Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. J Clin Invest. 2011;121(12):4700–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Nagarajah J, Le M, Knauf JA, Ferrandino G, Montero-Conde C, Pillarsetty N, et al. Sustained ERK inhibition maximizes responses of BrafV600E thyroid cancers to radioiodine. J Clin Invest. 2016;126(11):4119–24.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Ho AL, Grewal RK, Leboeuf R, Sherman EJ, Pfister DG, Deandreis D, et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med. 2013;368(7):623–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Takahashi M, Ritz J, Cooper GM. Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell. 1985;42(2):581–8.

    Article  CAS  PubMed  Google Scholar 

  55. Takahashi M, Buma Y, Iwamoto T, Inaguma Y, Ikeda H, Hiai H. Cloning and expression of the ret proto-oncogene encoding a tyrosine kinase with two potential transmembrane domains. Oncogene. 1988;3(5):571–8.

    CAS  PubMed  Google Scholar 

  56. Castellone MD, Santoro M. Dysregulated RET signaling in thyroid cancer. Endocrinol Metab Clin N Am. 2008;37(2):363–74. viii

    Article  CAS  Google Scholar 

  57. Heanue TA, Pachnis V. Enteric nervous system development and Hirschsprung’s disease: advances in genetic and stem cell studies. Nat Rev Neurosci. 2007;8(6):466–79.

    Article  CAS  PubMed  Google Scholar 

  58. Airaksinen MS, Saarma M. The GDNF family: signalling, biological functions and therapeutic value. Nat Rev Neurosci. 2002;3(5):383–94.

    Article  CAS  PubMed  Google Scholar 

  59. Tong Q, Xing S, Jhiang SM. Leucine zipper-mediated dimerization is essential for the PTC1 oncogenic activity. J Biol Chem. 1997;272(14):9043–7.

    Article  CAS  PubMed  Google Scholar 

  60. Monaco C, Visconti R, Barone MV, Pierantoni GM, Berlingieri MT, De Lorenzo C, et al. The RFG oligomerization domain mediates kinase activation and re-localization of the RET/PTC3 oncoprotein to the plasma membrane. Oncogene. 2001;20(5):599–608.

    Article  CAS  PubMed  Google Scholar 

  61. Grieco M, Santoro M, Berlingieri MT, Melillo RM, Donghi R, Bongarzone I, et al. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell. 1990;60(4):557–63.

    Article  CAS  PubMed  Google Scholar 

  62. Jhiang SM, Sagartz JE, Tong Q, Parker-Thornburg J, Capen CC, Cho JY, et al. Targeted expression of the ret/PTC1 oncogene induces papillary thyroid carcinomas. Endocrinology. 1996;137(1):375–8.

    Article  CAS  PubMed  Google Scholar 

  63. Powell Jr DJ, Russell J, Nibu K, Li G, Rhee E, Liao M, et al. The RET/PTC3 oncogene: metastatic solid-type papillary carcinomas in murine thyroids. Cancer Res. 1998;58(23):5523–8.

    CAS  PubMed  Google Scholar 

  64. Kondo T, Ezzat S, Asa SL. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer. 2006;6(4):292–306.

    Article  CAS  PubMed  Google Scholar 

  65. Bongarzone I, Vigneri P, Mariani L, Collini P, Pilotti S, Pierotti MA. RET/NTRK1 rearrangements in thyroid gland tumors of the papillary carcinoma family: correlation with clinicopathological features. Clin Cancer Res. 1998;4(1):223–8.

    CAS  PubMed  Google Scholar 

  66. Merolla F, Pentimalli F, Pacelli R, Vecchio G, Fusco A, Grieco M, et al. Involvement of H4(D10S170) protein in ATM-dependent response to DNA damage. Oncogene. 2007;26(42):6167–75.

    Article  CAS  PubMed  Google Scholar 

  67. Kirschner LS, Carney JA, Pack SD, Taymans SE, Giatzakis C, Cho YS, et al. Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex. Nat Genet. 2000;26(1):89–92.

    Article  CAS  PubMed  Google Scholar 

  68. Santoro M, Melillo RM, Fusco A. RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture. Eur J Endocrinol. 2006;155(5):645–53.

    Article  CAS  PubMed  Google Scholar 

  69. Santoro M, Dathan NA, Berlingieri MT, Bongarzone I, Paulin C, Grieco M, et al. Molecular characterization of RET/PTC3; a novel rearranged version of the RETproto-oncogene in a human thyroid papillary carcinoma. Oncogene. 1994;9(2):509–16.

    CAS  PubMed  Google Scholar 

  70. Leone V, Langella C, Esposito F, Arra C, Palma G, Rea D, et al. Ccdc6 knock-in mice develop thyroid hyperplasia associated to an enhanced CREB1 activity. Oncotarget. 2015;6(17):15628–38.

    Article  PubMed  PubMed Central  Google Scholar 

  71. Nikiforov YE, Rowland JM, Bove KE, Monforte-Munoz H, Fagin JA. Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res. 1997;57(9):1690–4.

    CAS  PubMed  Google Scholar 

  72. Ciampi R, Giordano TJ, Wikenheiser-Brokamp K, Koenig RJ, Nikiforov YE. HOOK3-RET: a novel type of RET/PTC rearrangement in papillary thyroid carcinoma. Endocr Relat Cancer. 2007;14(2):445–52.

    Article  CAS  PubMed  Google Scholar 

  73. Johannessen JV, Sobrinho-Simoes M. The origin and significance of thyroid psammoma bodies. Lab Investig. 1980;43(3):287–96.

    CAS  PubMed  Google Scholar 

  74. Tallini G, Santoro M, Helie M, Carlomagno F, Salvatore G, Chiappetta G, et al. RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. Clin Cancer Res. 1998;4(2):287–94.

    CAS  PubMed  Google Scholar 

  75. Viglietto G, Chiappetta G, Martinez-Tello FJ, Fukunaga FH, Tallini G, Rigopoulou D, et al. RET/PTC oncogene activation is an early event in thyroid carcinogenesis. Oncogene. 1995;11(6):1207–10.

    CAS  PubMed  Google Scholar 

  76. Sugg SL, Ezzat S, Rosen IB, Freeman JL, Asa SL. Distinct multiple RET/PTC gene rearrangements in multifocal papillary thyroid neoplasia. J Clin Endocrinol Metab. 1998;83(11):4116–22.

    CAS  PubMed  Google Scholar 

  77. Saad AG, Kumar S, Ron E, Lubin JH, Stanek J, Bove KE, et al. Proliferative activity of human thyroid cells in various age groups and its correlation with the risk of thyroid cancer after radiation exposure. J Clin Endocrinol Metab. 2006;91(7):2672–7.

    Article  CAS  PubMed  Google Scholar 

  78. Fugazzola L, Pilotti S, Pinchera A, Vorontsova TV, Mondellini P, Bongarzone I, et al. Oncogenic rearrangements of the RET proto-oncogene in papillary thyroid carcinomas from children exposed to the Chernobyl nuclear accident. Cancer Res. 1995;55(23):5617–20.

    CAS  PubMed  Google Scholar 

  79. Thomas GA, Bunnell H, Cook HA, Williams ED, Nerovnya A, Cherstvoy ED, et al. High prevalence of RET/PTC rearrangements in Ukrainian and Belarussian post-Chernobyl thyroid papillary carcinomas: a strong correlation between RET/PTC3 and the solid-follicular variant. J Clin Endocrinol Metab. 1999;84(11):4232–8.

    CAS  PubMed  Google Scholar 

  80. Ito T, Seyama T, Iwamoto KS, Mizuno T, Tronko ND, Komissarenko IV, et al. Activated RET oncogene in thyroid cancers of children from areas contaminated by Chernobyl accident. Lancet (London, England). 1994;344(8917):259.

    CAS  Google Scholar 

  81. Klugbauer S, Lengfelder E, Demidchik EP, Rabes HM. High prevalence of RET rearrangement in thyroid tumors of children from Belarus after the Chernobyl reactor accident. Oncogene. 1995;11(12):2459–67.

    CAS  PubMed  Google Scholar 

  82. Nikiforova MN, Stringer JR, Blough R, Medvedovic M, Fagin JA, Nikiforov YE. Proximity of chromosomal loci that participate in radiation-induced rearrangements in human cells. Science (New York, NY). 2000;290(5489):138–41.

    Article  CAS  Google Scholar 

  83. Gandhi M, Medvedovic M, Stringer JR, Nikiforov YE. Interphase chromosome folding determines spatial proximity of genes participating in carcinogenic RET/PTC rearrangements. Oncogene. 2006;25(16):2360–6.

    Article  CAS  PubMed  Google Scholar 

  84. Alipov G, Ito M, Prouglo Y, Takamura N, Yamashita S. Ret proto-oncogene rearrangement in thyroid cancer around Semipalatinsk nuclear testing site. Lancet (London, England). 1999;354(9189):1528–9.

    Article  CAS  Google Scholar 

  85. Oxford G, Theodorescu D. Ras superfamily monomeric G proteins in carcinoma cell motility. Cancer Lett. 2003;189(2):117–28.

    Article  CAS  PubMed  Google Scholar 

  86. Cox AD, Fesik SW, Kimmelman AC, Luo J, Der CJ. Drugging the undruggable RAS: mission possible? Nat Rev Drug Discov. 2014;13(11):828–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Hunt J. Understanding the genotype of follicular thyroid tumors. Endocr Pathol. 2005;16(4):311–21.

    Article  CAS  PubMed  Google Scholar 

  88. Castellano E, Santos E. Functional specificity of ras isoforms: so similar but so different. Genes Cancer. 2011;2(3):216–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  89. Jung CK, Little MP, Lubin JH, Brenner AV, Wells Jr SA, Sigurdson AJ, et al. The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations. J Clin Endocrinol Metab. 2014;99(2):E276–85.

    Article  CAS  PubMed  Google Scholar 

  90. Namba H, Gutman RA, Matsuo K, Alvarez A, Fagin JA. H-ras protooncogene mutations in human thyroid neoplasms. J Clin Endocrinol Metab. 1990;71(1):223–9.

    Article  CAS  PubMed  Google Scholar 

  91. Schulten HJ, Salama S, Al-Ahmadi A, Al-Mansouri Z, Mirza Z, Al-Ghamdi K, et al. Comprehensive survey of HRAS, KRAS, and NRAS mutations in proliferative thyroid lesions from an ethnically diverse population. Anticancer Res. 2013;33(11):4779–84.

    CAS  PubMed  Google Scholar 

  92. Zhu Z, Gandhi M, Nikiforova MN, Fischer AH, Nikiforov YE. Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations. Am J Clin Pathol. 2003;120(1):71–7.

    Article  CAS  PubMed  Google Scholar 

  93. De Micco C. ras mutations in follicular variant of papillary thyroid carcinoma. Am J Clin Pathol. 2003;120(5):803. author reply 4

    PubMed  Google Scholar 

  94. Lemoine NR, Mayall ES, Wyllie FS, Williams ED, Goyns M, Stringer B, et al. High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis. Oncogene. 1989;4(2):159–64.

    CAS  PubMed  Google Scholar 

  95. Suarez HG, du Villard JA, Severino M, Caillou B, Schlumberger M, Tubiana M, et al. Presence of mutations in all three ras genes in human thyroid tumors. Oncogene. 1990;5(4):565–70.

    CAS  PubMed  Google Scholar 

  96. Motoi N, Sakamoto A, Yamochi T, Horiuchi H, Motoi T, Machinami R. Role of ras mutation in the progression of thyroid carcinoma of follicular epithelial origin. Pathol Res Pract. 2000;196(1):1–7.

    Article  CAS  PubMed  Google Scholar 

  97. Wreesmann VB, Ghossein RA, Hezel M, Banerjee D, Shaha AR, Tuttle RM, et al. Follicular variant of papillary thyroid carcinoma: genome-wide appraisal of a controversial entity. Genes Chromosomes Cancer. 2004;40(4):355–64.

    Article  CAS  PubMed  Google Scholar 

  98. Chevillard S, Ugolin N, Vielh P, Ory K, Levalois C, Elliott D, et al. Gene expression profiling of differentiated thyroid neoplasms: diagnostic and clinical implications. Clin Cancer Res. 2004;10(19):6586–97.

    Article  CAS  PubMed  Google Scholar 

  99. Volante M, Rapa I, Gandhi M, Bussolati G, Giachino D, Papotti M, et al. RAS mutations are the predominant molecular alteration in poorly differentiated thyroid carcinomas and bear prognostic impact. J Clin Endocrinol Metab. 2009;94(12):4735–41.

    Article  CAS  PubMed  Google Scholar 

  100. Garcia-Rostan G, Zhao H, Camp RL, Pollan M, Herrero A, Pardo J, et al. ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. J Clin Oncol. 2003;21(17):3226–35.

    Article  CAS  PubMed  Google Scholar 

  101. Nikiforova MN, Lynch RA, Biddinger PW, Alexander EK, Dorn 2nd GW, Tallini G, et al. RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab. 2003;88(5):2318–26.

    Article  CAS  PubMed  Google Scholar 

  102. Milas M, Shin J, Gupta M, Novosel T, Nasr C, Brainard J, et al. Circulating thyrotropin receptor mRNA as a novel marker of thyroid cancer: clinical applications learned from 1758 samples. Ann Surg. 2010;252(4):643–51.

    PubMed  Google Scholar 

  103. Gupta N, Dasyam AK, Carty SE, Nikiforova MN, Ohori NP, Armstrong M, et al. RAS mutations in thyroid FNA specimens are highly predictive of predominantly low-risk follicular-pattern cancers. J Clin Endocrinol Metab. 2013;98(5):E914–22.

    Article  PubMed  PubMed Central  Google Scholar 

  104. Klein R, Jing SQ, Nanduri V, O’Rourke E, Barbacid M. The trk proto-oncogene encodes a receptor for nerve growth factor. Cell. 1991;65(1):189–97.

    Article  CAS  PubMed  Google Scholar 

  105. Hempstead BL, Martin-Zanca D, Kaplan DR, Parada LF, Chao MV. High-affinity NGF binding requires coexpression of the trk proto-oncogene and the low-affinity NGF receptor. Nature. 1991;350(6320):678–83.

    Article  CAS  PubMed  Google Scholar 

  106. Di Marco E, Mathor M, Bondanza S, Cutuli N, Marchisio PC, Cancedda R, et al. Nerve growth factor binds to normal human keratinocytes through high and low affinity receptors and stimulates their growth by a novel autocrine loop. J Biol Chem. 1993;268(30):22838–46.

    PubMed  Google Scholar 

  107. Djakiew D, Delsite R, Pflug B, Wrathall J, Lynch JH, Onoda M. Regulation of growth by a nerve growth factor-like protein which modulates paracrine interactions between a neoplastic epithelial cell line and stromal cells of the human prostate. Cancer Res. 1991;51(12):3304–10.

    CAS  PubMed  Google Scholar 

  108. Otten U, Ehrhard P, Peck R. Nerve growth factor induces growth and differentiation of human B lymphocytes. Proc Natl Acad Sci U S A. 1989;86(24):10059–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  109. Kaplan DR, Miller FD. Neurotrophin signal transduction in the nervous system. Curr Opin Neurobiol. 2000;10(3):381–91.

    Article  CAS  PubMed  Google Scholar 

  110. Pierotti MA, Bongarzone I, Borrello MG, Mariani C, Miranda C, Sozzi G, et al. Rearrangements of TRK proto-oncogene in papillary thyroid carcinomas. J Endocrinol Investig. 1995;18(2):130–3.

    Article  CAS  Google Scholar 

  111. Butti MG, Bongarzone I, Ferraresi G, Mondellini P, Borrello MG, Pierotti MA. A sequence analysis of the genomic regions involved in the rearrangements between TPM3 and NTRK1 genes producing TRK oncogenes in papillary thyroid carcinomas. Genomics. 1995;28(1):15–24.

    Article  CAS  PubMed  Google Scholar 

  112. Sozzi G, Bongarzone I, Miozzo M, Cariani CT, Mondellini P, Calderone C, et al. Cytogenetic and molecular genetic characterization of papillary thyroid carcinomas. Genes Chromosomes Cancer. 1992;5(3):212–8.

    Article  CAS  PubMed  Google Scholar 

  113. Greco A, Miranda C, Pagliardini S, Fusetti L, Bongarzone I, Pierotti MA. Chromosome 1 rearrangements involving the genes TPR and NTRK1 produce structurally different thyroid-specific TRK oncogenes. Genes Chromosomes Cancer. 1997;19(2):112–23.

    Article  CAS  PubMed  Google Scholar 

  114. Greco A, Pierotti MA, Bongarzone I, Pagliardini S, Lanzi C, Della PG. TRK-T1 is a novel oncogene formed by the fusion of TPR and TRK genes in human papillary thyroid carcinomas. Oncogene. 1992;7(2):237–42.

    CAS  PubMed  Google Scholar 

  115. Miranda C, Minoletti F, Greco A, Sozzi G, Pierotti MA. Refined localization of the human TPR gene to chromosome 1q25 by in situ hybridization. Genomics. 1994;23(3):714–5.

    Article  CAS  PubMed  Google Scholar 

  116. Greco A, Mariani C, Miranda C, Lupas A, Pagliardini S, Pomati M, et al. The DNA rearrangement that generates the TRK-T3 oncogene involves a novel gene on chromosome 3 whose product has a potential coiled-coil domain. Mol Cell Biol. 1995;15(11):6118–27.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  117. Shibata S, Matsuoka Y, Yoneda Y. Nucleocytoplasmic transport of proteins and poly(A)+ RNA in reconstituted Tpr-less nuclei in living mammalian cells. Genes Cells. 2002;7(4):421–34.

    Article  CAS  PubMed  Google Scholar 

  118. Green DM, Johnson CP, Hagan H, Corbett AH. The C-terminal domain of myosin-like protein 1 (Mlp1p) is a docking site for heterogeneous nuclear ribonucleoproteins that are required for mRNA export. Proc Natl Acad Sci U S A. 2003;100(3):1010–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  119. Park M, Dean M, Cooper CS, Schmidt M, O’Brien SJ, Blair DG, et al. Mechanism of met oncogene activation. Cell. 1986;45(6):895–904.

    Article  CAS  PubMed  Google Scholar 

  120. Greco A, Miranda C, Pierotti MA. Rearrangements of NTRK1 gene in papillary thyroid carcinoma. Mol Cell Endocrinol. 2010;321(1):44–9.

    Article  CAS  PubMed  Google Scholar 

  121. Roccato E, Bressan P, Sabatella G, Rumio C, Vizzotto L, Pierotti MA, et al. Proximity of TPR and NTRK1 rearranging loci in human thyrocytes. Cancer Res. 2005;65(7):2572–6.

    Article  CAS  PubMed  Google Scholar 

  122. Musholt TJ, Musholt PB, Khaladj N, Schulz D, Scheumann GF, Klempnauer J. Prognostic significance of RET and NTRK1 rearrangements in sporadic papillary thyroid carcinoma. Surgery. 2000;128(6):984–93.

    Article  CAS  PubMed  Google Scholar 

  123. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer (Oxford, England: 1990). 1997;33(5):787–91.

    Article  CAS  Google Scholar 

  124. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, et al. Specific association of human telomerase activity with immortal cells and cancer. Science (New York, NY). 1994;266(5193):2011–5.

    Article  CAS  Google Scholar 

  125. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57–70.

    Article  CAS  PubMed  Google Scholar 

  126. Liu T, Wang N, Cao J, Sofiadis A, Dinets A, Zedenius J, et al. The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas. Oncogene. 2014;33(42):4978–84.

    Article  CAS  PubMed  Google Scholar 

  127. Vinagre J, Almeida A, Populo H, Batista R, Lyra J, Pinto V, et al. Frequency of TERT promoter mutations in human cancers. Nat Commun. 2013;4:2185.

    Article  PubMed  CAS  Google Scholar 

  128. Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz Jr LA, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A. 2013;110(15):6021–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  129. Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A, et al. TERT promoter mutations in familial and sporadic melanoma. Science (New York, NY). 2013;339(6122):959–61.

    Article  CAS  Google Scholar 

  130. Liu X, Bishop J, Shan Y, Pai S, Liu D, Murugan AK, et al. Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocr Relat Cancer. 2013;20(4):603–10.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  131. Landa I, Ganly I, Chan TA, Mitsutake N, Matsuse M, Ibrahimpasic T, et al. Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease. J Clin Endocrinol Metab. 2013;98(9):E1562–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  132. Radkay LA, Chiosea SI, Seethala RR, Hodak SP, LeBeau SO, Yip L, et al. Thyroid nodules with KRAS mutations are different from nodules with NRAS and HRAS mutations with regard to cytopathologic and histopathologic outcome characteristics. Cancer Cytopathol. 2014;122(12):873–82.

    Article  CAS  PubMed  Google Scholar 

  133. Prior IA, Lewis PD, Mattos C. A comprehensive survey of Ras mutations in cancer. Cancer Res. 2012;72(10):2457–67.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  134. Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer. 2013;13(3):184–99.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  135. Nikiforov YE, Nikiforova MN. Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol. 2011;7(10):569–80.

    Article  CAS  PubMed  Google Scholar 

  136. Fagin JA. Minireview: branded from the start-distinct oncogenic initiating events may determine tumor fate in the thyroid. Mol Endocrinol (Baltimore, MD). 2002;16(5):903–11.

    CAS  Google Scholar 

  137. Kroll TG, Sarraf P, Pecciarini L, Chen CJ, Mueller E, Spiegelman BM, et al. PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]. Science (New York, NY). 2000;289(5483):1357–60.

    Article  CAS  Google Scholar 

  138. Au AY, McBride C, Wilhelm Jr KG, Koenig RJ, Speller B, Cheung L, et al. PAX8-peroxisome proliferator-activated receptor gamma (PPARgamma) disrupts normal PAX8 or PPARgamma transcriptional function and stimulates follicular thyroid cell growth. Endocrinology. 2006;147(1):367–76.

    Article  CAS  PubMed  Google Scholar 

  139. Pasca di Magliano M, Di Lauro R, Zannini M. Pax8 has a key role in thyroid cell differentiation. Proc Natl Acad Sci U S A. 2000;97(24):13144–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  140. Damante G, Tell G, Di Lauro R. A unique combination of transcription factors controls differentiation of thyroid cells. Prog Nucleic Acid Res Mol Biol. 2001;66:307–56.

    Article  CAS  PubMed  Google Scholar 

  141. Kozmik Z, Kurzbauer R, Dorfler P, Busslinger M. Alternative splicing of Pax-8 gene transcripts is developmentally regulated and generates isoforms with different transactivation properties. Mol Cell Biol. 1993;13(10):6024–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  142. Poleev A, Fickenscher H, Mundlos S, Winterpacht A, Zabel B, Fidler A, et al. PAX8, a human paired box gene: isolation and expression in developing thyroid, kidney and Wilms’ tumors. Development (Cambridge, England). 1992;116(3):611–23.

    CAS  Google Scholar 

  143. Wang T, Xu J, Yu X, Yang R, Han ZC. Peroxisome proliferator-activated receptor gamma in malignant diseases. Crit Rev Oncol Hematol. 2006;58(1):1–14.

    Article  PubMed  Google Scholar 

  144. Krishnan A, Nair SA, Pillai MR. Biology of PPAR gamma in cancer: a critical review on existing lacunae. Curr Mol Med. 2007;7(6):532–40.

    Article  CAS  PubMed  Google Scholar 

  145. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem. 1995;270(22):12953–6.

    Article  CAS  PubMed  Google Scholar 

  146. Lui WO, Zeng L, Rehrmann V, Deshpande S, Tretiakova M, Kaplan EL, et al. CREB3L2-PPARgamma fusion mutation identifies a thyroid signaling pathway regulated by intramembrane proteolysis. Cancer Res. 2008;68(17):7156–64.

    Article  CAS  PubMed  Google Scholar 

  147. Drieschner N, Belge G, Rippe V, Meiboom M, Loeschke S, Bullerdiek J. Evidence for a 3p25 breakpoint hot spot region in thyroid tumors of follicular origin. Thyroid. 2006;16(11):1091–6.

    Article  CAS  PubMed  Google Scholar 

  148. Dwight T, Thoppe SR, Foukakis T, Lui WO, Wallin G, Hoog A, et al. Involvement of the PAX8/peroxisome proliferator-activated receptor gamma rearrangement in follicular thyroid tumors. J Clin Endocrinol Metab. 2003;88(9):4440–5.

    Article  CAS  PubMed  Google Scholar 

  149. Hou P, Ji M, Xing M. Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3-kinase/AKT signaling pathway in thyroid tumors. Cancer. 2008;113(9):2440–7.

    Article  CAS  PubMed  Google Scholar 

  150. Saji M, Ringel MD. The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors. Mol Cell Endocrinol. 2010;321(1):20–8.

    Article  CAS  PubMed  Google Scholar 

  151. Sansal I, Sellers WR. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol. 2004;22(14):2954–63.

    Article  CAS  PubMed  Google Scholar 

  152. Wu G, Mambo E, Guo Z, Hu S, Huang X, Gollin SM, et al. Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors. J Clin Endocrinol Metab. 2005;90(8):4688–93.

    Article  CAS  PubMed  Google Scholar 

  153. Eng C. Will the real Cowden syndrome please stand up: revised diagnostic criteria. J Med Genet. 2000;37(11):828–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  154. Halachmi N, Halachmi S, Evron E, Cairns P, Okami K, Saji M, et al. Somatic mutations of the PTEN tumor suppressor gene in sporadic follicular thyroid tumors. Genes Chromosomes Cancer. 1998;23(3):239–43.

    Article  CAS  PubMed  Google Scholar 

  155. Dahia PL, Marsh DJ, Zheng Z, Zedenius J, Komminoth P, Frisk T, et al. Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors. Cancer Res. 1997;57(21):4710–3.

    CAS  PubMed  Google Scholar 

  156. Patel HH, Goyal N, Goldenberg D. Imaging, genetic testing, and biomarker assessment of follicular cell-derived thyroid cancer. Ann Med. 2014;46(6):409–16.

    Article  CAS  PubMed  Google Scholar 

  157. Geisbrecht BV, Gould SJ. The human PICD gene encodes a cytoplasmic and peroxisomal NADP(+)-dependent isocitrate dehydrogenase. J Biol Chem. 1999;274(43):30527–33.

    Article  CAS  PubMed  Google Scholar 

  158. Hemerly JP, Bastos AU, Cerutti JM. Identification of several novel non-p.R132 IDH1 variants in thyroid carcinomas. Eur J Endocrinol. 2010;163(5):747–55.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, University of North Carolina, 4001 Burnett-Womack Building, CB #7050, Chapel Hill, NC, 27599-7050, USA

    Laura N. Purcell M.D.

  2. Division of Surgical Oncology and Endocrine Surgery, Department of Surgery, University of North Carolina, CB7213, 170 Manning Drive, 1150 POB, Chapel Hill, NC, 27599-7213, USA

    Jen Jen Yeh M.D.

Authors
  1. Laura N. Purcell M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jen Jen Yeh M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Laura N. Purcell M.D. .

Editor information

Editors and Affiliations

  1. General Surgery, Central Arkansas Veterans Healthcare System, University of Arkansas, Little Rock, Arkansas, USA

    Anne T. Mancino

  2. Division of Surgical Oncology, University of North Carolina, Chapel Hill, North Carolina, USA

    Lawrence T. Kim

Rights and permissions

Reprints and permissions

Copyright information

© 2017 The Author(s)

About this chapter

Cite this chapter

Purcell, L.N., Yeh, J.J. (2017). Molecular Genetics of Thyroid Cancer. In: Mancino, A., Kim, L. (eds) Management of Differentiated Thyroid Cancer. Springer, Cham. https://doi.org/10.1007/978-3-319-54493-9_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-54493-9_2

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-54492-2

  • Online ISBN: 978-3-319-54493-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation